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The characteristics and response rate to pegy-
lated interferon and ribavirin (PEG-INF þ RBV)
of patients with chronic hepatitis C infected with
genotype 5 are poorly documented. A meta-
analysis of two large phase III/IV prospective
randomized clinical trials conducted in Belgium
in patients with chronic hepatitis C (n ¼ 1,073
patients) was performed in order to compare
the response to antiviral therapy of hepatitis C
virus (HCV) genotype 5 with that of other HCV
genotypes. A subset of HCV-1 infected patients
selected from within the study database were
selected to match the HCV-5 sample for known
prognostic factors. In Belgium HCV-5 is respon-
sible for a signiﬁcant minority of cases of chronic
hepatitis C CHC (4.5%) and is characterized by a
moreadvancedage (58.4 years), a high frequency
of cirrhosis (27.7%), a speciﬁcmodeofHCVacqui-
sition, and a particular geographic origin (66.7%
of patients from West Flanders). The primary
comparative analysis showed that response to
treatment with PEG-INF þ RBV of HCV-5 is
similar to HCV-1 and lower compared to HCV-2/
3. The analysis of the matched patient subgroup
demonstrates that the HCV-5 ‘‘intrinsic sensi-
tivity’’ to PEG-IFN þ RBV therapy is identical to
HCV-1, with a sustained virological response of
55% in both groups. In contrast to previous pub-
lications, this meta-analysis suggests that HCV-5
response to treatment is closer to HCV-1 than to
HCV-2/3 and suggests that in Belgium HCV-5
infection should be treated with the same
antiviral regimen as HCV-1. J. Med. Virol.
83:815–819, 2011.  2011 Wiley-Liss, Inc.
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INTRODUCTION
At least sixmajor genotypes of hepatitisCvirus (HCV)
have been identiﬁed, each comprising multiple sub-
types. HCV genotype 5 (HCV-5) shows a worldwide
distribution mainly restricted to South Africa where it
has been observed in up to 30% ofHCV infected patients
[Simmonds, 1995]. In other parts of theworld genotype5
is a minor component of the population infected with
HCV [Blatt et al., 2000; Ross et al., 2000] except in a few
restricted areas of higher prevalence [Jover et al., 2001;
Henquell et al., 2004; Verbeeck et al., 2007]. In Belgium,
the overall prevalence of HCV infection is estimated to
be 0.9% of the population according to HCV antibody
screening [Beutels et al., 1997] and the repartition of
genotypes reﬂects the trends inEurope and theUS: 68%
genotype 1, 23% genotypes 2 or 3, and 3, 9% other
genotypes [Kleter et al., 1998; Gerard et al., 2005].
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Relatively little sequence heterogeneity is found
within genotype 5 [Chamberlain et al., 1997; Verbeeck
et al., 2005]. The characteristics and response rate of
patientswith chronic hepatitis C infectedwithHCV-5 to
interferon-based therapy has been poorly documented
todate, but the suggestion is thatHCV-5 respondsbetter
to therapy thanHCV-1 [Legrand-Abravanel et al., 2004;
Delwaide et al., 2005; Bonny et al., 2006; Antaki et al.,
2008]. An accurate comparison of the sensitivity of
genotype 5 to treatment with other better known gen-
otypes should allow a better evaluation of response to
treatment and will help to deﬁne the optimal treatment
regimen of this rare genotype. Because of the small size
of the genotype 5 population large single studies are
difﬁcult to perform. Meta-analyses and matched sub-
group analysis of genotype 5 response to treatment are
analternative. Two large clinical trialswhoassessed the
antiviral effect of pegylated interferon and ribavirin
(PEG-INF þ RBV) have been performed in Belgium.
They offer a unique opportunity for studying patients
with chronic hepatitis C infected by HCV-5.
MATERIALS AND METHODS
In order to compare the efﬁcacy of antiviral therapy on
HCV-5 with other genotypes, a meta-analysis of two
large phase III/IV prospective randomized clinical trials
conducted in Belgium in chronic hepatitis C naı¨ve
patients and relapsers (BERNAR 1 and BERNAR 2)
has been performed [Langlet et al., 2009; Nevens
et al., 2010]. The designs of both studies are summarized
in Figure 1. For the meta-analysis the statistician had
direct access to the individual patient data.
Both studies were conducted in full compliance with
Good Clinical Practice standards with applicable
Belgian laws and with the principles laid down in the
revised version of the Declaration of Helsinki as
reﬂected in an a priori approval by the institution’s
human research committee. As per protocol, informed
consent was obtained from each patient after adequate
explanation of the methods, objectives, and potential
hazards of the study had been fully explained. The
meta-analysis of the HCV-5 subgroup of patients was
planned by protocol and a speciﬁc statistical analytical
plan was issued prior to any analysis.
Both studies were designed to evaluate the safety and
efﬁcacy of pegylated interferon alpha and ribavirin
therapy in a large population of patients with chronic
hepatitis C. In both studies, the backbone therapy con-
sisted of pegylated interferon alpha-2a (180 mg/week by
sc route) and ribavirin (RBV) (1,000–1,200 mg po daily
according to HCV genotype and body weight). Patients
were treated for 24 (genotypes 2 and 3) or 48 (genotypes
1, 4, 5, and 6) weeks according toHCV genotype, accord-
ing to internationally recommended practices [Fried
et al., 2002]. The deﬁnitions of the endpoints were
similar in both studies and also the inclusion and exclu-
sion criteria were similar. International accepted rules
for dose adaptation and interruption of treatment were
used [Fried et al., 2002]. HCV RNA was measured in
both studies with the AMPLICORHCVMONITOR test
V2.0.
Themeta-analysis compared patient baseline charac-
teristics, early virological response, response at 24 and
48 weeks of treatment, end-of-treatment response, sus-
tained virological response, and relapse rate between,
respectively, HCV-5 and HCV-1, and HCV-5, and HCV-
2/3. For the purposes of consistency, only patients
treated with pegylated interferon alpha-2a plus riba-
virin (PEG-IFN þ RBV) in both studies were included
in the analysis of response to treatment. Since many
amantadineHCVstudies, including ourBENAR2 study
and a recent meta-analysis showed that there was no
effect of adding this drug, also patients who received
amantadine together with PEG-INF þ RBV were
included in the analysis [Deltenre et al., 2004; Langlet
Fig. 1. The designs of the BENAR 1 and BENAR 2 trials which assessed the response rate of pegylated
interferon alpha-2a and ribavirin in patients with chronic hepatitis C in Belgium.
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et al., 2009]. The meta-analysis was done on the patient
group who received at least one dose of study
medication.
In addition, a subset of patients infected with HCV-1
selected from the studies databases tomatch the HCV-5
sample according to age category (< vs. 40), gender,
baseline viral load (< vs. 800,000 IU/ml), cirrhosis
(yes vs. no), pretreatment status (naı¨ve vs. relapsers),
and treatment received was compared to the HCV-5
patients. As in the previous analyses only patients
treated PEG-IFN þ RBV were selected.
Statistical Analysis
Categorical variables were compared using Fisher’s
exact test and continuous variables using Student’s
t-test. Stepwise logistic regression analyses were per-
formedusingamultivariate stepwise regression for end-
of-treatment response, sustained virological response,
and relapse rate. All statistical tests were performed at
the 5% level of signiﬁcance.
RESULTS
In total, 1,073 patients were recruited, from October
2000 to May 2005, in both studies of which 48 (4.5%)
were of HCV-5 genotype. The distribution of genotypes
of the patient population is given in Table I. The
observed repartition of genotypes conﬁrmed the pre-
dominance of genotypes 1, 2, and 3 but revealed a rather
higher prevalence of HCV-5 in Belgium compared to
other European countries and the USA.
Characteristics of the Patients
Main patient baseline characteristics are shown in
Table II. HCV-5 patients are predominantly females
from West Flanders. The mean age is 58 years, they
are not infected by intravenous drug abuse and have
more advanced liver disease. Among HCV-5, 60.4% of
patients are female, compared to 32.8% in HCV-2/3
(P < 0.001). Mean ages in years are, respectively, 58.4
for HCV-5, 40.2 for HCV-2/3 (P < 0.001), and 47.3 for
HCV-1 (P < 0.001). Cirrhosis was present in 27.7% of
HCV-5 and in 15.1% of HCV-2/3, this difference is stat-
istically signiﬁcant (P ¼ 0.037). The mode of HCV-5
acquisition is signiﬁcantly different from both HCV-1
and HCV-2/3, most frequently this is unknown followed
by transfusion. Only one single intravenous drug-
associated case was identiﬁed suffering from HCV-5.
Response to Treatment
For this purpose only patients who received PEG-
INF þ RBV: genotype 1 patients n ¼ 485, genotypes 2
and 3 n ¼ 249, and genotype 5 n ¼ 38. Treatment
response is presented in Table III. Sustained virological
response is 55.6% in HCV-5 which is very close to that
seen in HCV-1 (50%) but lower, although not reaching
statistical signiﬁcance than in HCV-2/3 (75%). Early
virological response (week 12) is lowest in HCV-5
(50%) and signiﬁcantly different from that in HCV-2/3
(87.8%; P < 0.001). Response at end of treatment is also
signiﬁcantly lower in HCV-5 than in HCV-2/3.
In the sample of matched patients, the ‘‘intrinsic sen-
sitivity’’ of HCV-5 was shown to be identical to that of
HCV-1 with a sustained virological response equal to
55.3% (21/38) in both matched groups (P ¼ 1.000).
The multivariate analysis indicates that early viro-
logical response, genotype andHCVviral load at screen-
ing have a statistically signiﬁcant impact on the rate of
sustained virological response and that genotype, viral
load at screening and treatment status (relapsers vs.
naı¨ve patients) are prognostic indicators of a sustained
virological response.
DISCUSSION
The response rate to interferon-based therapy of
patients infected with HCV-5 has been poorly docu-
mented and it has been suggested that HCV-5 patients
respond better to therapy than HCV-1 patients
[Legrand-Abravanel et al., 2004; Delwaide et al.,
2005; Bonny et al., 2006]. However, this is based on
retrospective data in small groups of patients treated
with different kind of interferons with different dosages
and treatment durations. This study is the ﬁrst com-
parative analysis of HCV-5 response to pegylated inter-
feron-based therapy derived from two large prospective
randomized clinical trials. It has allowed better charac-
terization of the Belgian HCV-5 population and the
response to treatment in comparison to other genotypes.
TABLE I. The Distribution of the Different Genotypes in the Study Population
Study All patients
BERNAR 1 BERNAR 2
Number %Number % Number %
Genotype
1 279 62.9 338 53.7 617 57.5
2 31 7.0 42 6.7 73 6.8
3 76 17.2 156 24.8 232 21.6
4 34 7.7 66 10.5 100 9.3
5 22 5.0 26 4.0 48 4.5
6 1 0.2 2 0.3 3 0.3
Total 443 100.00 630 100.00 1,073 100.00
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Our HCV-5 population is characterized by a rather
advanced age (58.4 years), a high frequency of cirrhosis
(27.7%), a speciﬁc mode of HCV acquisition (mainly
blood transfusion), and a particular geographic origin
(66.7% of patients from West Flanders). This suggests
that the infection in these patients occurredmany years
ago by blood transfusion in a speciﬁc region of Belgium.
Genotype 5 is found frequently in South Africa. It was
found that the Belgian and South African strains form
two distinct clusters of similar diversity [Verbeeck et al.,
2006].
In this studyHCV-5demonstrated a response to treat-
ment similar to HCV-1 and a lower response to treat-
ment compared to HCV-2/3. An analysis of matched
patients demonstrates further that theHCV-5 ‘‘intrinsic
sensitivity’’ to PEG-IFN þ RBV combined therapy is
indeed identical to HCV-1.
Therefore, in contrast to previous published studies,
this meta-analysis suggests that HCV-5 patient
response to treatment is more similar to that seen with
HCV-1 than to HCV-2/3 and, that HCV-5 patients
should probably be treated with the same antiviral
therapy regimen as HCV-1 patients.
REFERENCES
AntakiN,HermesA,HadadM,FtayehM,Antaki F, AbdoN,Kebbewar
K. 2008. Efﬁcacy of interferon plus ribavirin in the treatment of
hepatitits C virus genotype 5. J Viral Hepat 15:383–386.
Beutels M, VanDamme P, AelvoetW, Desmyter J, Dondeyne F, Goilav
C, Mak R, Muylle L, Pierard D, Stroobant A, Van Loock F, Wau-
mans P, Vranckx R. 1997. Prevalence of hepatitis A, B and C in the
Flemish population. Eur J Epidemiol 13:275–280.
Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B,
Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P,
McHutchison JG. 2000. Assessment of hepatitis C virus RNA
and genotype from 6807 patients with chronic hepatitis C in the
United States. J Viral Hepatol 7:196–202.
Bonny C, Fontaine H, Poynard T, He´zode C, Larrey D, Marcellin P,
Bourlie`re M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guille-
mard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K,
Bommelaer G, Abergel A. 2006. Effectiveness of interferon plus
ribavirin combination in the treatment of naı¨ve patients with
hepatitis C virus type 5. A French multicentre retrospective study.
Aliment Pharmacol Ther 24:593–600.
Chamberlain RW, Adams NJ, Taylor LA, Simmonds P, Elliott RM.
1997. The complete coding sequence of hepatitis C virus genotype
TABLE III. Response to Treatment by Genotype
Genotype 1, n ¼ 485 (%) Genotype 2/3, n ¼ 249 (%) Genotype 5, n ¼ 38 (%)
Virological response at week 12 65.9 87.8 50.0a
Virological response at week 24 71.4 81.8 66.7
End of treatment response 68.8 82.4 59.3a
Sustained virological response 50.0 75.0 55.3a
Relapse Rate 23.9 7.2 12.5
aGenotype 5 versus 2/3: P < 0.001.
TABLE II. Main Patients Baseline Characteristics by Genotype of The Total Study Population (n ¼ 1,073)
Genotype
1 2/3 5
Geographic origin, n (%)
West Flanders 61/617 (9.8%) 34/305 (11.1%) 32/48 (66.7%)
Gender, n (%)
Male 329/617 (53.4%) 205/305 (67.2%) 19/48 (39.6%)
Female 288/617 (46.6%) 100/305 (32.8%) 29/48 (60.4%)
Mean age, years 47.3 40.2 58.1a
Caucasian, n (%) 588/617 (95.3%) 275/305 (90.2%) 47/48 (97.9%)
Mean BMI (kg/m2) 25.4 24.5 26.4
Mode of HCV acquisition (%)
Unknown 202/617 (32.7%) 66/305 (21.6%) 22/48 (45.8%)
Transfusion 211/617 (34.2%) 43/305 (14.1%) 19/48 (39.6%)
Drug use 142/617 (23.0%) 166/305 (54.4%) 1/48 (2.1%)a,b
Cirrhosis (%) 113/617 (18.3%) 46/305 (15.1%) 13/48 (27.7%)c
Treatment status, n (%)
Naive 528/617 (85.6%) 276/305 (90.5%) 44/48 (91.7%)
Relapsers 89/617 (14.4%) 29/305 (9.5%) 4/48 (8.3%)
HCV  800,000 IU/ml, n (%) 266/612 (43.5%) 138/304 (45.4%) 23/48 (47.9%)
ALT (%)
<2 ULN 354/617 (57.4%) 145/305 (47.6%) 23/48 (47.9%)
2 to <5 ULN 226/617 (36.6%) 114/305 (37.4%) 22/48 (45.8%)
5 ULN 37/617 (6.0%) 46/305 (15%) 3/48 (6.3%)
ULN, upper limit of normality.
aGenotype 5 versus 2/3: P < 0.001.
bGenotype 5 versus 1: P < 0.001.
cGenotype 5 versus 2/3: P < 0.037.
818 D’Heygere et al.
J. Med. Virol. DOI 10.1002/jmv
5a, the predominant genotype in South Africa. Biochem Biophys
Res Commun 236:44–49.
Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A,
De Maeght S, Paris JC, Mathurin P. 2004. Evaluation of amanta-
dine in chronic hepatitis C: A meta-analysis. J Hepatol 41:462–
473.
Delwaide J, Gerard C, Reenaers C, Vaira D, Bastens B, Bataille C,
Servais B, Maes B, Belaiche J, Hepatotropes GL, Groupe Liegeois
D’etudesDesVirusHepatotropes (GLEVE). 2005.Hepatitis C virus
genotype 5 in southern Belgium: Epidemiological characteristics
and respons to therapy. Dig Dis Sci 50:2348–2351.
FriedMW,ShiffmanML,ReddyKR, SmithC,MarinosG,Goncales FL,
Jr., HaussingerD,DiagoM,Carrosi G, DhumauxD, Craxi A, LinA,
Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin
for chronic hepatitis C virus infection. N Engl J Med 347:975–
982.
Gerard C, Delwaide J, Vaira D, Bastens B, Servais B, Wain E, Bataille
C,DaenenG,Belaı¨cheJ. 2005.Evolution over a10 year period of the
epidemiological proﬁle of 1726 newly diagnosed HCV patients in
Belgium. J Med Virol 76:503–510.
Henquell C, Carteau C, Abergel A, Laurichesse H, Regagnon C,
DeChampsC, Bailly JL, Peigue-LafeuilleH. 2004.High prevalence
of hepatitis C virus Type 5 in Central France evidenced by a pro-
spective study from 1996 to 2002. Clin J Microbial 42:3030–3035.
Jover R, Pe´rez-Serra J, de Vera F, Alamo JM, Mun˜oz C, Yago C,
Martı´nez-Ramı´rez R, Vidal JV. 2001. Infection by genotype 5a of
HCV in a district of southeast Spain. Am J Gastroenterol 96:3042–
3043.
Kleter B, Brouwer JT, Nevens F, van Doorn LJ, Elewaut A, Versieck J,
Michielsen PP, Hautekeete ML, Chamuleau RA, Bre´nard R, Bour-
geoisN,AdlerM,QuintWG,Bronkhorst CM,HeijtinkRA,HopWJ,
Fevery J, Schalm SW. 1998. Hepatitis C virus genotypes: Epide-
miological and clinical associations. The Benelux Study Group on
treatments of chronic hepatitis C. Liver 18:32–38.
Langlet P, D’Heygere F, Henrion J, Adler M, Delwaide J, Van
Vlierberghe H, Mulkay JP, Lasser L, Brenard R, Horsmans Y,
Michielsen P, Laureys A, Nevens F. 2009. A randomized trial of
pegylated-interferon-a-2a plus ribavirin with or without amanta-
dine in treatment-naı¨ve or relapsing chronic hepatitis C patients.
Aliment Pharmacol Ther 30:352–363.
Legrand-AbravanelF,Sandres-Saune´K,BarangeK,AlricL,MoreauJ,
Desmorat P, Vinel JP, Izopet J. 2004. Hepatitis C virus genotype 5:
Epidemiological characteristics and sensitivity to combination
therapy with interferon-a plus ribaverin. J Infect Dis 189:1397–
1400.
Nevens F, Van Vlierberghe H, D’Heygere F, Delwaide J, Adler M,
Henrion J, Lenaerts A, Hendlisz A, Michielsen P, Bastens B,
Brenard R, Laureys A, the BERNAR-1 Study Group. 2010. A
randomized, open-label, multicenter study evaluation the efﬁcacy
of peginterferon alfa-2a versus interferon alfa-2a, in combination
with ribavirin, in naı¨ve and relapsed chronic hepatitis C patients.
Acta Gastroenterol Belg 73:223–228.
Ross RS, Viazov S, Renzing-Ko¨hler K, Roggendorf M. 2000. Changes in
the epidemiology of hepatitis C infection in Germany: Shift in the
predominance of hepatitis C subtypes. J Med Virol 60:122–125.
SimmondsP. 1995. Variability of hepatitis C virus.Hepatology 21:570–
581.
Verbeeck J, Maes P, Wollants E, Van der Merwe S, Song E, Nevens F,
VanRanstM.2005.Useof a commercially available lineprobe assay
for genotyping of hepatitis C virus 5a strains. J Clin Microbiol
43:6117–6119.
VerbeeckJ,MaesP,LemeyP,PybusOG,WollantsE,SongE,NevensF,
Fevery J, Delport W, Van der Merwe S, Van Ranst M. 2006. Inves-
tigating the origin and spread of Hepatitis C virus genotype 5a.
J Virol 80:4220–4226.
Verbeeck J, Peigne-Lafeuille H, Ross S, Abergel A, Nevens F, Van der
Merwe S, Van Ranst M. 2007. HCV genotype 5: Epidemiology and
spread of an uncommon genotype. J Clin Virol 41:170–171.
Treatment of Genotype 5 819
J. Med. Virol. DOI 10.1002/jmv
